Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Malignant Melanoma

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 44 articles: HTML format

Single Articles

March 2023
1. 
   Erratum: COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
   J Clin Oncol. 2023 Mar 8:JCO2300385. doi: 10.1200/JCO.23.00385.
   PubMed    
   
   
   February 2023
2. DEVLIN O, Oladipo O
   Sequencing of Targeted Treatment and Immunotherapy in Advanced BRAF-Mutant Melanoma.
   J Clin Oncol. 2023 Feb 15:JCO2202250. doi: 10.1200/JCO.22.02250.
   PubMed    
   
   
   
3. ASCIERTO PA, Lipson EJ, Dummer R, Larkin J, et al
   Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
   J Clin Oncol. 2023 Feb 13:JCO2202072. doi: 10.1200/JCO.22.02072.
   PubMed     Abstract available
   
   
   
4. TOPALIAN SL, Sznol M, McDermott DF, Kluger HM, et al
   Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
   J Clin Oncol. 2023;41:943-954.
   PubMed     Abstract available
   
   
   
5. SCHWARTZ GK
   Flashback Foreword: Nivolumab in Advanced Melanoma: Survival and Long-Term Safety.
   J Clin Oncol. 2023;41:941-942.
   PubMed    
   
   
   January 2023
6. KIRKWOOD JM, Strawderman MH, Ernstoff MS, Smith TJ, et al
   Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.
   J Clin Oncol. 2023;41:425-435.
   PubMed     Abstract available
   
   
   
7. SCHWARTZ GK
   Flashback Foreword: Adjuvant Interferon alpha-2b for High-Risk Melanoma.
   J Clin Oncol. 2023;41:423-424.
   PubMed    
   
   
   December 2022
8. MANGLA A
   Dissecting the Need for Adjuvant Therapy in Patients With Early-Stage Melanoma With Micrometastases.
   J Clin Oncol. 2022 Dec 1:JCO2201903. doi: 10.1200/JCO.22.01903.
   PubMed    
   
   
   
9. HINDIE E
   Risk of Overusing Sentinel Node Biopsy in Patients With Thin Melanoma.
   J Clin Oncol. 2022 Dec 1:JCO2201963. doi: 10.1200/JCO.22.01963.
   PubMed    
   
   
   November 2022
10. BOUFFET E, Geoerger B, Moertel C, Whitlock JA, et al
    Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.
    J Clin Oncol. 2022 Nov 14:JCO2201000. doi: 10.1200/JCO.22.01000.
    PubMed     Abstract available
    
    
    September 2022
11. ATKINS MB, Lee SJ, Chmielowski B, Tarhini AA, et al
    Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial - ECOG-ACRIN EA6134.
    J Clin Oncol. 2022 Sep 27:101200JCO2201763. doi: 10.1200/JCO.22.01763.
    PubMed     Abstract available
    
    
    
12. WEBER JS, Schadendorf D, Del Vecchio M, Larkin J, et al
    Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
    J Clin Oncol. 2022 Sep 26:JCO2200533. doi: 10.1200/JCO.22.00533.
    PubMed     Abstract available
    
    
    
13. AUGUSTIN RC, Luke JJ
    Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma.
    J Clin Oncol. 2022 Sep 26:JCO2201770. doi: 10.1200/JCO.22.01770.
    PubMed    
    
    
    
14. CHANDRA S, Choi JS, Sosman JA
    Melanoma: Does Sequencing Really Matter?
    J Clin Oncol. 2022 Sep 20:JCO2201354. doi: 10.1200/JCO.22.01354.
    PubMed    
    
    
    
15. ASCIERTO PA, Mandala M, Ferrucci PF, Guidoboni M, et al
    Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
    J Clin Oncol. 2022 Sep 1:JCO2102961. doi: 10.1200/JCO.21.02961.
    PubMed     Abstract available
    
    
    August 2022
16. CHESNEY JA, Ribas A, Long GV, Kirkwood JM, et al
    Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
    J Clin Oncol. 2022 Aug 23:JCO2200343. doi: 10.1200/JCO.22.00343.
    PubMed     Abstract available
    
    
    July 2022
17. ARANCE A, de la Cruz-Merino L, Petrella TM, Jamal R, et al
    Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
    J Clin Oncol. 2022 Jul 22:JCO2200221. doi: 10.1200/JCO.22.00221.
    PubMed     Abstract available
    
    
    
18. DUMMER R, Flaherty KT, Robert C, Arance A, et al
    COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
    J Clin Oncol. 2022 Jul 21:JCO2102659. doi: 10.1200/JCO.21.02659.
    PubMed     Abstract available
    
    
    
19. SULLIVAN RJ
    What, if Any, Role Is There for BRAF-Targeted Therapy in BRAF-Mutant Melanoma?
    J Clin Oncol. 2022 Jul 21:JCO2201066. doi: 10.1200/JCO.22.01066.
    PubMed    
    
    
    
20. MONCRIEFF MD, Lo SN, Scolyer RA, Heaton MJ, et al
    Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
    J Clin Oncol. 2022 Jul 18:JCO2102488. doi: 10.1200/JCO.21.02488.
    PubMed     Abstract available
    
    
    June 2022
21. GARBE C, Keim U, Amaral T, Berking C, et al
    Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
    J Clin Oncol. 2022 Jun 16:JCO2200202. doi: 10.1200/JCO.22.00202.
    PubMed     Abstract available
    
    
    
22. SETH R, Messersmith H, Funchain P
    Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Jun 3:JCO2200944. doi: 10.1200/JCO.22.00944.
    PubMed     Abstract available
    
    
    March 2022
23. OLIVIER T, Prasad V
    Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial.
    J Clin Oncol. 2022 Mar 8:JCO2102904. doi: 10.1200/JCO.21.02904.
    PubMed    
    
    
    
24. CARVAJAL RD, Nathan P, Sacco JJ, Orloff M, et al
    Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
    J Clin Oncol. 2022 Mar 7:JCO2101805. doi: 10.1200/JCO.21.01805.
    PubMed     Abstract available
    
    
    February 2022
25. PIRES DA SILVA I, Ahmed T, McQuade JL, Nebhan CA, et al
    Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
    J Clin Oncol. 2022 Feb 10:JCO2101701. doi: 10.1200/JCO.21.01701.
    PubMed     Abstract available
    
    
    January 2022
26. CALLAHAN MK, Chapman PB
    PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.
    J Clin Oncol. 2022 Jan 14:JCO2102801. doi: 10.1200/JCO.21.02801.
    PubMed    
    
    
    
27. DUMMER R, Long GV, Robert C, Tawbi HA, et al
    Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
    J Clin Oncol. 2022 Jan 14:JCO2101601. doi: 10.1200/JCO.21.01601.
    PubMed     Abstract available
    
    
    December 2021
28. POSTOW MA, Goldman DA, Shoushtari AN, Betof Warner A, et al
    Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
    J Clin Oncol. 2021 Dec 20:JCO2101570. doi: 10.1200/JCO.21.01570.
    PubMed     Abstract available
    
    
    November 2021
29. WOLCHOK JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, et al
    Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
    J Clin Oncol. 2021 Nov 24:JCO2102229. doi: 10.1200/JCO.21.02229.
    PubMed     Abstract available
    
    
    August 2021
30. ANDTBACKA RHI, Curti B, Daniels GA, Hallmeyer S, et al
    Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
    J Clin Oncol. 2021 Aug 31:JCO2003246. doi: 10.1200/JCO.20.03246.
    PubMed     Abstract available
    
    
    July 2021
31. DIAB A, Tykodi SS, Daniels GA, Maio M, et al
    Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
    J Clin Oncol. 2021 Jul 13:JCO2100675. doi: 10.1200/JCO.21.00675.
    PubMed     Abstract available
    
    
    June 2021
32. HUPPERT LA, Daud AI
    Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma.
    J Clin Oncol. 2021 Jun 17:JCO2100943. doi: 10.1200/JCO.21.00943.
    PubMed    
    
    
    
33. CHAPMAN PB
    Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.
    J Clin Oncol. 2021 Jun 4:JCO2101012. doi: 10.1200/JCO.21.01012.
    PubMed    
    
    
    May 2021
34. SARNAIK AA, Hamid O, Khushalani NI, Lewis KD, et al
    Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
    J Clin Oncol. 2021 May 12:JCO2100612. doi: 10.1200/JCO.21.00612.
    PubMed     Abstract available
    
    
    
35. OLSON DJ, Eroglu Z, Brockstein B, Poklepovic AS, et al
    Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
    J Clin Oncol. 2021 May 4:JCO2100079. doi: 10.1200/JCO.21.00079.
    PubMed     Abstract available
    
    
    February 2021
36. EL SHAROUNI MA, Ahmed T, Varey AHR, Elias SG, et al
    Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas.
    J Clin Oncol. 2021 Feb 18:JCO2002446. doi: 10.1200/JCO.20.02446.
    PubMed     Abstract available
    
    
    January 2021
37. SHOUSHTARI AN
    Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003523. doi: 10.1200/JCO.20.03523.
    PubMed    
    
    
    
38. HINDIE E
    Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003213. doi: 10.1200/JCO.20.03213.
    PubMed    
    
    
    
39. YAN X, Sheng X, Chi Z, Si L, et al
    Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 14:JCO2000902. doi: 10.1200/JCO.20.00902.
    PubMed     Abstract available
    
    
    
40. PIULATS JM, Espinosa E, de la Cruz Merino L, Varela M, et al
    Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    J Clin Oncol. 2021 Jan 8:JCO2000550. doi: 10.1200/JCO.20.00550.
    PubMed     Abstract available
    
    
    
41. KHAN S, Carvajal RD
    Dual Immunological Checkpoint Blockade for Uveal Melanoma.
    J Clin Oncol. 2021 Jan 8:JCO2003274. doi: 10.1200/JCO.20.03274.
    PubMed    
    
    
    October 2020
42. PELSTER MS, Gruschkus SK, Bassett R, Gombos DS, et al
    Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
    J Clin Oncol. 2020 Oct 30:JCO2000605. doi: 10.1200/JCO.20.00605.
    PubMed     Abstract available
    
    
    September 2020
43. ROBERT C, Long GV, Brady B, Dutriaux C, et al
    Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.
    J Clin Oncol. 2020 Sep 30:JCO2000995. doi: 10.1200/JCO.20.00995.
    PubMed     Abstract available
    
    
    April 2020
44. TAYLOR MH, Lee CH, Makker V, Rasco D, et al
    Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    J Clin Oncol. 2020;38:1154-1163.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: